Akebia Therapeutics, Inc.

Healthcare

NASDAQ:AKBA · NASDAQ Global Market

Market Cap $241.27M Beta 0.25 P/E (TTM) -12.0

$0.92 +2.79%

+$0.03 today

52W Low $0.82High $4.08

Vol 5.23M · Avg 3.66M

EPS (TTM)-$0.08

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

-74.03%

Period High

$4.01

Period Low

$0.87

Latest

$0.92

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

$1.44B

Ventyx Biosciences, Inc.

VTYX

$1.00B

Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

$1.00B

Olema Pharmaceuticals, Inc.

NASDAQ:OLMA

$862.12M

Zevra Therapeutics, Inc.

NASDAQ:ZVRA

$747.81M

Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

$607.79M

4D Molecular Therapeutics, Inc.

NASDAQ:FDMT

$461.60M

Prothena Corporation plc

NASDAQ:PRTA

$431.91M

Compass Therapeutics, Inc.

NASDAQ:CMPX

$280.72M

Gossamer Bio, Inc.

GOSS

$38.00M

What is the latest AKBA filing?

The latest filing shown is SC 13G dated May 12, 2026.

How many recent filings does AKBA have?

Intrinsic Alpha currently shows 20 recent filings for AKBA.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.